Skip to main content

Clinical Trials

Clinical and outcomes research under the direction of the Department of Dermatology is conducted both at the Northwestern University Feinberg School of Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago dermatology clinics. For more information about the research or participation, please call our office at 312-503-5944.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about our work via the Feinberg Office of Research Clinical Trials page.

Trials

DERMATOLOGY TISSUE ACQUISITION AND REPOSITORY

This study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of …
This study is collecting skin, hair, nail, blood,saliva, skin and/or buccal swabs, and mucous membrane (part of your skin which lines bodypassages and cavities such as the inside of your mouth or nose), and other tissue samples for usein a biorepository. By operating this biorepository, the Department of Dermatology hopes todevelop a better understanding of skin diseases (meaning the knowledge about how cells in theskin behave and react to medical treatments) among researchers at Northwestern University andother approved researchers. This basic knowledge is expected to help the development of moreeffective patient care and new treatment methods.
  • Consent to have specimens collected as part of a standard of care procedure
  • Have a skin disease diagnosis which researchers want samples of in order to further understand the disease
  • Qualify as a healthy volunteer (a person with no skin disease)
Rangel, Stephanie MarieRangel, Stephanie Marie
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00009443
More Info
Copy

Epidermolysis Bullosa Clinical Characterization and Outcomes Database

The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, …

The aim this study is to collaboratively advance knowledge about epidermolysis bullosa (EB) by collecting clinical data from patients with EB from multiple EB centers in the United States and Canada. As EB is a rare disease, coordination and collaboration between multiple centers will help our understanding of disease manifestations, course, and complications, with the aim of improving future care, expanding clinical and translational research, and finding an eventual cure for individuals with EB.

All candidates with a clinical diagnosis of epidermolysis bullosa are eligible for this study.  The subjects can be from any age, male or female without restriction.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00202682
More Info
Copy

Characterization of the microbiome in cutaneous T cell lymphoma

The purpose of this study is to investigate the organisms that reside on the skin, in the gut, and nasal cavity and study their relationship with Cutaneous T-Cell Lymphoma (CTCL).
  • Be between the ages of 18-89
  • Be able and willing to provide informed consent
  • You must not have cutaneous t-cell lymphoma (CTCL)
  • You must not be currently pregnant
  • You must not be on or exposed to systemic antibiotics with 4 weeks of beginning study participation
Zhou, AlanZhou, Alan
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00209226
More Info
Copy

A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects ((≥6 To <18 Years of Age)

The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. …

The purpose of this research study is to see if guselkumab is safe and effective for treating patients with chronic plaque psoriasis, and to find out how long guselkumab stays in and acts on the body and how the body reacts to it. This is shown by laboratory blood tests. Another purpose is to find out if guselkumab can cause side effects (unexpected or unwanted reactions from taking a drug).

You could be in this study if:

  • You are 6 to 17 years old
  • A doctor has said you have chronic plaque psoriasis
  • You have had chronic plaque psoriasis for at least 6 months
  • You have taken medication for your psoriasis, but it hasn’t worked

Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
NCT03451851 STU00209613
More Info
Copy

A Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions

The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who …

The purpose of this research is to observe patients with skin conditions in a ‘real world’ setting and to create an patient registry of skin conditions, to better understand these diseases and how they are treated. A patient registry is a collection of information about a group of patients who share a condition or experience.

Additionally, researchers are interested in:

  • Observing how skin condition treatments work and understand side effects caused by these medicines and how these are managed
  • Identifying other types of conditions associated with skin disorders
  • Collecting patient reported outcomes to better understand the patient perspective and feelings patients have about having a skin condition
  • Assessing the impact of Patient Support Programs for individuals with skin conditions and how these programs affect skin condition outcomes
  • Creating a “Biorepository Specimen Bank” with blood and saliva samples

  • Have a skin condition such as Atopic Dermatitis, Psoriasis, Alopecia, Vitiligo, Hidradenitis Suppurativa and others.
  • You will not be asked to take any medications as part of this study.
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00209616
More Info
Copy

Impact of immunotherapy-related skin diseases on quality of life

The purpose of this study is to characterize the effects of cutaneous side effects from immunotherapies on quality of life. Participants will complete a one time survey. 
Participants need to be 18 years and older, receiving immunotherapy, and may be experiencing a dermatologic side effect. 
Choi, Jennifer NamChoi, Jennifer Nam
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00212205
More Info
Copy

Tape Strip Analysis in Dermatologic Diseases

The main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples …
The main purpose of this study is to better understand the characteristics of various dermatologic diseases compared to healthy controls. The research team will do this by acquiring tape strips from subjects, a quick, painless, and non-invasive way to obtain skin cells. This study will collect tape strip samples from a broad range of dermatologic diseases, which may include psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, and other rare conditions, in addition to healthy controls. 
  • Have a dermatologic disease such as psoriasis, epidermolysis bullosa, atopic dermatitis, ichthyosis, or other rare skin condition
  • Be a healthy volunteer (someone with no dermatologic disease)
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00213591
More Info
Copy

A Prospective and Retrospective Clinical, Histological and Molecular Analysis of the Spectrum of Cutaneous Presentations in Adult Patients Admitted to the Hospital

The purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting.…

The purpose of this study is to better characterize and understand the spectrum of skin disease evaluated in the inpatient hospital setting.

  • Be older than 18
  • Be admitted to Northwestern Memorial Hospital or evaluated in the Emergency Department for whom an inpatient dermatology consultation is requested.

Nguyen, CuongNguyen, Cuong
  • Map it 251 E. Huron St.
    Chicago, IL
STU00212714
More Info
Copy

A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris

The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells …

The purpose of this study is to determine the highest dose of the study drug that can be given safely to patients with pemphigus vulgaris. The study will test how the study drug affects desmoglein 3 (DSG3) autoantibody amounts in your body. DSG3 is responsible for holding together the cells lining the inside of the mouth, nose, throat, eyelids and genitals, causing the painful blisters commonly seen in patients with pemphigus vulgaris. The study will also look at how long the study drug stays in your body, and if the study drug improves the symptoms that you are experiencing with the pemphigus vulgaris.

  • Must be at least 18 years of age
  • Have a confirmed diagnosis of mucosal-dominant pemphigus vulgaris or have a prior positive demoglein 3-ELISA result (a pemphigus vulgaris diagnostic tool) and confirmed by biopsy at the screening visit
  • Have pemphigus vulgaris that has previously been inadequately managed by at least one prior standard therapy
Zhou, AlanZhou, Alan
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT04422912 STU00214626
More Info
Copy

A Phase 3 Study of Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects

This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.…

This study is being done to evaluate the safety and tolerability of tapinarof cream, 1% in children and adolescents with plaque psoriasis. This study will also measure the quantity of the study drug in your blood, if any. The efficacy, how well the study drug works, will also be evaluated.

  • Be 2-17 years old
  • Have a clinical diagnosis of chronic plaque psoriasis and stable disease for at least 3 months
  • Have involvement of plaque psoriasis on at least 3% of the body, excluding the scalp
Paller, AmyPaller, Amy
  • Map it 225 E. Chicago Ave.
    Chicago, IL
STU00216645
More Info
Copy

Investigation of Sleep and Health Outcomes in Women Reporting Normal and Heavy Menses Flow

We are interested in understanding how the menstrual cycle and severity of menses (lheavier menstrual flow) affects sleep.

  • Be between the ages of 18 and 50
  • Pre-menopausal with regular menstrual cycles every 21-35 days
  • Self-report 3 to 7 days of flow in menstruation
  • Have an intact uterus and at least 1 ovary
  • Not currently or soon to be pregnant
  • Not using an IUD (unless copper)
  • Not regularly using sleep aids
Walter, JessicaWalter, Jessica
  • Map it 676 N. St. Clair St.
    Chicago, IL
STU00215465
More Info
Copy

Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, …

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.

  • Patient must be 18 years of age or older.
  • Patient must have pathologically confirmed T or NK cell lymphoma. For CTCL, patients with stage IB disease or greater are eligible.
  • Relapse or refractory disease after at least 1 systemic therapy
  • No prior therapy with ruxolitinib
  • Patient must not be pregnant
  • No concurrent illness/disease or other systemic therapies unrelated to T-cell lymphoma
Choi, JaehyukChoi, Jaehyuk
  • Map it 676 N. St. Clair St.
    Chicago, IL
NCT02974647 STU00216438
More Info
Copy

Development and Validation of an Ancillary Diagnostic Test for Mycosis Fungoides (SIGNAL MF)

As the number of available treatments for CTCL grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment …

As the number of available treatments for CTCL grow, there is a need to find a way to identify which treatment will work best for each subject. The goal of this study is to develop a test called a gene expression assay to see if the assay can predict treatment success and/or failure in subjects with CTCL.

Patient who has a diagnosis of mycosis fungoides (MF).

Patient who is between 2-89 years of age.

Patient who is willing and able to provide new skin samples via superficial scraping at least one affected and non-affected body site.

Guitart, JoanGuitart, Joan
STU00217977
More Info
Copy

Combing topical imiquimod with local radiotherapy treatment of mycosis fungoides

The primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) mycosis fungoides (MF). Subjects will be asked to use the imiquimod cream at designated lesions nightly for 5 consecutive days a week …

The primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) mycosis fungoides (MF). Subjects will be asked to use the imiquimod cream at designated lesions nightly for 5 consecutive days a week over 6 weeks. One week into the imiquimod treatment course, radiation therapy will be administered at Northwestern Medicine by radiation oncologists familiar with radiation treatment in 2 fractions of 4 Gy (units of radiation absorbed by the patient) (total 8 Gy) over 2 days to the same designated lesions. In addition, subjects will have two skin biopsies during the screening period and again at the same locations at week 8.

Patients must have confirmed stage IA-IIB mycosis fungoides, have failed at least one standard therapy for MF, have active, but stable disease for at least 6 months with 4 or more discrete lesions (with at least 2 lesions >50cm2 in area combined). Patients of child bearing potential must have a negative pregnancy test before enrolling on the study.

Zhou, AlanZhou, Alan
  • Map it 676 N. Saint Clair St. Suite 1600
    Chicago, IL
NCT05838599 STU00218514
More Info
Copy

Hair Disorder Registry

The purpose of this study is to collect characteristic data from patients with medical conditions affecting hair health using medical records and surveys. The main benefit of being in this study is to provide future benefit to patients with acquired and congenital hair disorders and the providers who care for …

The purpose of this study is to collect characteristic data from patients with medical conditions affecting hair health using medical records and surveys.

The main benefit of being in this study is to provide future benefit to patients with acquired and congenital hair disorders and the providers who care for them by adding to our understanding of normal hair physiology, causes and mechanisms of disease, clinical and molecular features, natural history, and treatment outcomes.

12 years and older with primary or secondary involvement of hair follicle disease

Colavincenzo, Maria LColavincenzo, Maria L
  • Map it 676 N. Saint Clair St. Suite 1600
    Chicago, IL
STU00219310
More Info
Copy

An Open-Label Study of Dupilumab in Adolescent and Adult Skin-of-Color Patients with Moderate-to-Severe Atopic Dermatitis

The study is focused on skin-of-color participants who have moderate-to-severe atopic dermatitis. For the purposes of this research study, “skin-of-color” refers to participants with Fitzpatrick types 4, 5, and 6. Fitzpatrick skin type is a commonly used system to describe a person’s skin …

The study is focused on skin-of-color participants who have moderate-to-severe atopic dermatitis. For the purposes of this research study, “skin-of-color” refers to participants with Fitzpatrick types 4, 5, and 6. Fitzpatrick skin type is a commonly used system to describe a person’s skin response to ultraviolet radiation (UVR) exposure. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants.

Liszewski, Walter JosephLiszewski, Walter Joseph
  • Map it 676 N. Saint Clair St. Suite 1600
    Chicago, IL
NCT05590585 STU00218376
More Info
Copy

Follow Dermatology on